Literature DB >> 15990735

Smoking cessation in patients with coronary artery disease.

Jason Ludvig1, Brienne Miner, Mark J Eisenberg.   

Abstract

BACKGROUND: Smoking cessation is an important factor in the primary and secondary prevention of cardiac events. Although multiple clinical trials have examined the efficacy of various smoking cessation aids, a systematic review of the efficacy and safety of smoking cessation aids has not been done.
METHODS: This paper reviews the effects of smoking on coronary artery disease. In addition, we identify randomized controlled trials examining the efficacy and safety of smoking cessation aids from the years 1970 to 2004. We then pooled the trial results for 6- and 12-month rates of continuous smoking abstinence.
RESULTS: The 4 principal mechanisms of cardiovascular damage caused by cigarette smoking are induction of a hypercoagulable state, reduction of oxygen delivery because of carbon monoxide, coronary vasoconstriction, and nicotine-induced hemodynamic effects. Our review of clinical trials suggests that each smoking cessation aid improved continuous smoking abstinence rates at both 6 and 12 months compared with placebo. The 12-month abstinence rates for the active versus placebo treatments were the following: nicotine patch 11.1% versus 5.5%, nicotine gum 27.3% versus 16.5%, nicotine inhaler 16.9% versus 9.1%, bupropion 18.5% versus 6.6%, and behavioral therapy 20.0% versus 13.9%.
CONCLUSIONS: Several smoking-related mechanisms are responsible for the development of atherosclerosis and the induction of cardiac events. Smoking cessation aids effect a modest increase in smoking abstinence at 12 months compared with placebo. In spite the apparent success of cessation aids, smoking relapse rates are quite high.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990735     DOI: 10.1016/j.ahj.2004.09.040

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

1.  Smoking, smoking cessation, and risk of cardiovascular disease.

Authors:  Peter W F Wilson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

2.  Promoting smoking cessation during hospitalization for coronary artery disease.

Authors:  Robert D Reid; Andrew L Pipe; Bonnie Quinlan
Journal:  Can J Cardiol       Date:  2006-07       Impact factor: 5.223

3.  Safety of nicotine replacement therapy in critically ill smokers: a retrospective cohort study.

Authors:  Michael A Gillies; C A McKenzie; C Whiteley; R J Beale; S M Tibby
Journal:  Intensive Care Med       Date:  2012-05-23       Impact factor: 17.440

Review 4.  Tailoring nicotine replacement therapy: rationale and potential approaches.

Authors:  Jennifer B McClure; Gary E Swan
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Nicotine preference and affective behavior of Cd81 knockout mice.

Authors:  R Logan Murphy; Laura L Locklear; M Haris Niaz; Rebecca L Walton; Alexandra D Hudson; Karl J Fryxell
Journal:  Psychopharmacology (Berl)       Date:  2021-09-07       Impact factor: 4.530

6.  [Risk factor management of coronary heart disease : what is evidence-based?].

Authors:  E B Winzer; G C Schuler
Journal:  Herz       Date:  2014-06       Impact factor: 1.443

Review 7.  Lifestyle Modification in Secondary Prevention: Beyond Pharmacotherapy.

Authors:  Jenna Brinks; Amy Fowler; Barry A Franklin; Jassu Dulai
Journal:  Am J Lifestyle Med       Date:  2016-07-08

8.  European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Int J Behav Med       Date:  2012-12

9.  Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study.

Authors:  Christian Madsen; Per Nafstad; Lars Eikvar; Per E Schwarze; Kjersti S Rønningen; Lise Lund Haaheim
Journal:  Eur J Epidemiol       Date:  2007-05-05       Impact factor: 12.434

Review 10.  The use of bupropion SR in cigarette smoking cessation.

Authors:  Scott Wilkes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.